MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma

J. Scott Lee, Sarah Tang, Veronica Ortiz, Thanh‐Trang Vo

Oncotarget · 2015 · 27 citations · 50 references

DOIFull text

Open access

Concepts

Abstract

// J. Scott Lee 1 , Sarah S. Tang 1 , Veronica Ortiz 1 , Thanh-Trang Vo 1 and David A. Fruman 1 1 Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA Correspondence to: David A. Fruman, email: // Keywords : lymphoma, apoptosis, PI3K, mTOR, BCL-2 Received : August 19, 2015 Accepted : September 24, 2015 Published : October 09, 2015 Abstract The PI3K/AKT/mTOR axis promotes survival and is a frequently mutated pathway in cancer. Yet, inhibitors targeting this pathway are insufficient to induce cancer cell death as single agents in some contexts, including diffuse large B cell lymphoma (DLBCL). In these situations, combinations with inhibitors targeting BCL-2 survival proteins (ABT-199 and ABT-263) may hold potential. Indeed, studies have demonstrated marked synergy in contexts where PI3K/mTOR inhibitors suppress expression of the pro-survival protein, MCL-1. In this study, we use BH3 profiling to confirm that BCL-2 and BCL-X L support survival following PI3K pathway inhibition, and that the dual PI3K/mTOR inhibitor BEZ235 strongly synergizes with BCL-2 antagonists in DLBCL. However, we identify an alternative mechanism of synergy between PI3K/mTOR and BCL-2 inhibitors, independent of MCL-1 down-regulation. Instead, we show that suppression of AKT activation by BEZ235 can induce the mitochondrial accumulation of pro-apoptotic BAD and BIM, and that expression of a constitutively active form of AKT prevents sensitization to BCL-2 antagonism. Thus, our work identifies an additional mechanism of synergy between PI3K pathway inhibitors and BCL-2 antagonists that strengthens the rationale for testing this combination in DLBCL.

References

50